- Report
- July 2026
- 130 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 130 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- July 2026
- 110 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- June 2026
- 115 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- May 2026
- 140 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- April 2026
- 180 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- April 2026
- 110 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- August 2026
- 324 Pages
Global
From €2212EUR$2,500USD£1,896GBP
- Report
- May 2026
- 138 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- May 2026
- 149 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 142 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 136 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 144 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 148 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- March 2026
- 141 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 160 Pages
Global
From €2938EUR$3,320USD£2,517GBP
€3672EUR$4,150USD£3,147GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP
- Report
- June 2026
- 160 Pages
Global
From €2477EUR$2,799USD£2,122GBP
€3096EUR$3,499USD£2,653GBP
- Report
- February 2026
- 160 Pages
Global
From €2938EUR$3,320USD£2,517GBP
€3672EUR$4,150USD£3,147GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more